首页> 外文OA文献 >Real-World Analysis of Clinical Characters, Prognosis, And Recurrence Pattern: A Retrospective Multicenter Study of 429 Patients with Epidermal Growth Factor Receptor (EGFR) Mutant Locally Advanced Non-Small Cell Lung Cancer (LA-NSCLC)

【2h】

Real-World Analysis of Clinical Characters, Prognosis, And Recurrence Pattern: A Retrospective Multicenter Study of 429 Patients with Epidermal Growth Factor Receptor (EGFR) Mutant Locally Advanced Non-Small Cell Lung Cancer (LA-NSCLC)

机译：真实世界分析临床特征，预后和复发模式：429例表皮生长因子受体（EGFR）突变体局部晚期非小细胞肺癌的回顾性多中心研究（LA-NSCLC）

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
K. Xu; N. BI; H. Ge; M. E; L. Zhang; J. Cao; X. Zhang; B. Xia; L. Zhao; J. Li; C. Hu; L. Wang;
展开▼
作者单位

展开▼
年度 2020
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Phase II Trial of Cabozantinib Plus Erlotinib in Patients With Advanced Epidermal Growth Factor Receptor ( EGFR)-Mutant Non-small Cell Lung Cancer With Progressive Disease on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy: A California Cancer Consortium Phase II Trial (NCI 9303) [J] . Karen L. Reckamp, Paul H. Frankel, Nora Ruel, Frontiers in Oncology . 2019,第2016期

机译：卡巴替尼+厄洛替尼在晚期表皮生长因子受体（ EGFR ）-突变型非小细胞肺癌中进展性疾病的表皮生长因子受体酪氨酸激酶抑制剂治疗的II期临床试验：加利福尼亚癌症协会II期试验（NCI 9303）
2. Phase II Trial of Cabozantinib Plus Erlotinib in Patients With Advanced Epidermal Growth Factor Receptor ( EGFR)-Mutant Non-small Cell Lung Cancer With Progressive Disease on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy: A California Cancer Consortium Phase II Trial (NCI 9303) [J] . Karen L. Reckamp, Paul H. Frankel, Nora Ruel, Frontiers in Oncology . 2019,第4期

机译：卡巴替尼+厄洛替尼在晚期表皮生长因子受体（ EGFR ）-突变型非小细胞肺癌中进展性疾病的表皮生长因子受体酪氨酸激酶抑制剂治疗的II期临床试验：加利福尼亚癌症协会II期试验（NCI 9303）
3. MuTAR study, Phase II, open-label study of erlotinib (E) treatment in patients (pts) with locally advanced or metastatic non-small cell lung cancer (mNSCLC) who present activating mutations (MUT+) in the tyrosine kinase (TKI) domain of the epidermal growth factor receptor (EGFR), assessed the efficacy of 1L in Portuguese pts with mNSCLC EGFR Mut+ [J] . F. Barata, H. Queiroga, E. Teixeira, Revista Portuguesa de Pneumologia (English Edition) . 2016,第5期

机译：MuTAR研究，II期，开放标签研究厄洛替尼（E）治疗在局部晚期或转移性非小细胞肺癌（mNSCLC）患者中出现酪氨酸激酶（TKI）域激活突变（MUT +）的患者（pts）表皮生长因子受体（EGFR）的研究，通过mNSCLC EGFR Mut +评价了1L在葡萄牙患者中的疗效
4. Machine Learning-powered Prediction of Recurrence in Patients with Non-small Cell Lung Cancer Using Quantitative Clinical and Radiomic Biomarkers [C] . Sehwa Moon, Dahim Choi, Ji-Yeon Lee, Medical Imaging Conference . 2020

机译：使用定量学习和放射生物标志物的机器学习技术预测非小细胞肺癌患者的复发
5. Predictive Biomarkers of the Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Treating Advanced Non-small Cell Lung Cancer: A Systematic Review of Randomized Controlled Trials [D] . Yang, Zuyao. 2014

机译：表皮生长因子受体酪氨酸激酶抑制剂治疗晚期非小细胞肺癌疗效的预测生物标志物：随机对照试验的系统评价。
6. A Real-World Observational Prospective Study to Assess the Molecular Epidemiology of Epidermal Growth Factor Receptor (EGFR) Mutations upon Progression on or after First-Line Therapy with a First- or Second-Generation EGFR Tyrosine Kinase Inhibitor in EGFR Mutation-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer: The ‘LUNGFUL’ Study [O] . Giannis Mountzios, Anna Koumarianou, Alexandros Bokas, 2021

机译：真实世界观测性前瞻性研究以评估表皮生长因子受体（EGFR）突变的分子流行病学在一线治疗中或二进代EGFR酪氨酸激酶抑制剂在EGFR突变局部局部先进或转移性非小细胞肺癌：悠久的研究
7. A Real-World, Observational, Prospective Study to Assess the Molecular Epidemiology of Epidermal Growth Factor Receptor (EGFR) Mutations upon Progression on or after First-Line Therapy with a First or Second Generation EGFR Tyrosine Kinase Inhibitor in EGFR Mutation-Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer: The ‘LUNGFUL’ Study [O] . Giannis Mountzios, Anna Koumarianou, Alexandros Bokas, 2021

机译：一个现实世界，观测的，前瞻性研究，评估在一线治疗的前进过程中的表皮生长因子受体（EGFR）突变的分子流行病学与EGFR突变阳性局部先进或者的第一代或第二代EGFR酪氨酸激酶抑制剂转移性非小细胞肺癌：“悠久”的研究

Real-World Analysis of Clinical Characters, Prognosis, And Recurrence Pattern: A Retrospective Multicenter Study of 429 Patients with Epidermal Growth Factor Receptor (EGFR) Mutant Locally Advanced Non-Small Cell Lung Cancer (LA-NSCLC)

著录项

相似文献

相关主题

期刊订阅